Tim Mayleben

Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI.

Part of MKS Instruments, Inc., Applied Intelligent Systems, Inc. is a company that manufactures machine vision computers. The company is based in Ann Arbor, MI. Applied Intelligent Systems was acquired by Electro Scientific Industries, Inc., part of MKS Instruments, Inc. from February 01, 2019 on December 02, 1997 for $60.55 million.

Transom Technologies, Inc. develops 3-D simulation and modeling software. The company is based in Ann Arbor, MI. Transom Technologies was acquired by Engineering Animation, Inc. on September 23, 1998 for $13 million.

Founded in 1998 by Roger Newton and Timothy Mayleben, Esperance BioVentures LLC is a venture capital firm located in Ann Arbor, Michigan

Michigan Ross Zell Lurie Institute / Venture Capital/ (Zell Lurie Institute) is a venture capital subsidiary of Zell Lurie Institute for Entrepreneurial Studies Studies founded in 1997 by Samuel Zell, Ann Lurie and Robert H. Lurie. The firm is headquartered in Ann Arbor, Michigan.

Wolverine Venture Fund, an evergreen fund invests in companies located in the US. The fund targets companies that are affiliated with the University of Michigan and operating in the fields of biomedicine, healthcare IT, advanced materials, and other emerging technologies. It provides financing for seed and early-stage capital requirements with an investment size ranging from $50,000 to $100,000 and also makes co-investment rights.

Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT.